September 21, 2015
Tri-Institutional Therapeutics Discovery Institute launches new Request for Proposals
The Tri-Institutional Therapeutics Discovery Institute program is designed to identify early-stage drug development projects with strong potential to benefit patients and effectively advance them into proof-of-concept studies. Through its unique partnership with Takeda Pharmaceutical Company, the Tri-I TDI is able to offer investigators highly sophisticated expertise in medicinal chemistry.
The new request for proposals results from several ongoing Tri-I TDI projects moving from hit-to-lead studies to lead optimization, freeing up resources for new projects to enter the portfolio. To ensure that the most promising and transformative projects are chosen in an unbiased manner, the institute relies on a Scientific Advisory Board of prominent scientists and thought leaders from its three member institutions as well as the biopharmaceutical industry and the venture capital community.
The Tri-TDI is accepting letters of intent for new projects until September 30. Applicants whose projects fit well with the program's criteria will be notified by October 12 and asked to submit a full application by November 13. Awards will be announced on Dec. 11.
Learn more about the program and how to apply on our Applications page.
- September 9, 2014 The Weill Cornell Medical College presents the MILSTEIN PROGRAM IN MEDICINAL CHEMISTRY SYMPOSIUM: FROM TARGET TO TREATMENT
- October 1, 2013 Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda
A global, research-based pharmaceutical company with a strong record for bringing new medicines to market, Takeda will provide medicinal chemists and pharmacologists to work on the development of small molecules.